Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria.

Combination antimalarial therapy may delay the spread of drug resistance, but clinical data supporting this notion are limited. For 1 year, we studied Ugandan children who were treated for uncomplicated malaria with sulfadoxine-pyrimethamine (SP), SP + amodiaquine (AQ), or SP + artesunate (AS). We compared treatment responses and the prevalence of resistance-conferring mutations of new infections with those of recrudescent infections due to parasites that survived prior treatment. Recrudescent infections were associated with the selection of SP resistance-conferring mutations in all treatment groups, but responses to repeat therapy differed. Compared with initial treatments, treatment of recrudescent infections was associated with a higher rate of treatment failure (hazard ratio [HR], 2.44; P=.01), for the SP group, but with a lower rate of treatment failure (HR, 0.40; P=.08), for the SP + AS group. Treatment failure in the SP + AQ group was uncommon, limiting the analysis of recrudescent parasites. Our results suggest that the use of combination antimalarial therapy in Africa may slow the spread of drug-resistant malaria and prolong the therapeutic life span of available treatment regimens.

[1]  P. Rosenthal,et al.  Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. , 2003, The American journal of tropical medicine and hygiene.

[2]  A. Hubbard,et al.  Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. , 2003, The American journal of tropical medicine and hygiene.

[3]  S. Meshnick,et al.  Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. , 2003, The American journal of tropical medicine and hygiene.

[4]  P. Rosenthal,et al.  Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial , 2002, The Lancet.

[5]  N. White.  The assessment of antimalarial drug efficacy. , 2002, Trends in parasitology.

[6]  A. Mr.  Severe and complicated malaria. , 2002 .

[7]  F. Cobelens,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[8]  C. Wendo.  African scientists discuss drug-resistant malaria , 2002, The Lancet.

[9]  J. Kublin,et al.  Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. , 2002, The Journal of infectious diseases.

[10]  E. Nduati,et al.  Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania , 2001, The Lancet.

[11]  P. Rosenthal,et al.  Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial , 2001, The Lancet.

[12]  P. Ringwald,et al.  Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. , 2000, The American journal of tropical medicine and hygiene.

[13]  C. Wongsrichanalai,et al.  Antimalarial drug combination policy: a caveat , 2000, The Lancet.

[14]  A. Nzila,et al.  The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. , 2000, The American journal of tropical medicine and hygiene.

[15]  K. Bojang,et al.  Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.

[16]  P. Olliaro,et al.  Averting a malaria disaster , 1999, The Lancet.

[17]  G. Langsley,et al.  A primary malarial infection is composed of a very wide range of genetically diverse but related parasites. , 1998, The Journal of clinical investigation.

[18]  M. Duraisingh,et al.  Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. , 1998, Experimental parasitology.

[19]  R. Snow,et al.  Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria , 1997, Antimicrobial agents and chemotherapy.

[20]  R. Price,et al.  Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  B. Metchock,et al.  Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. , 1996, The American journal of tropical medicine and hygiene.

[22]  R. Price,et al.  Effects of artemisinin derivatives on malaria transmissibility , 1996, The Lancet.

[23]  S. Meshnick,et al.  Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. , 1996, Microbiological reviews.

[24]  O. Doumbo,et al.  Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. , 1995, The American journal of tropical medicine and hygiene.

[25]  N. White,et al.  Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. , 1994, The Journal of infectious diseases.

[26]  P. Phillips-Howard,et al.  The epidemiology of drug-resistant malaria. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[28]  J. Trape.  The public health impact of chloroquine resistance in Africa. , 2001, The American journal of tropical medicine and hygiene.

[29]  P. Bloland,et al.  Combination therapy for malaria in Africa: hype or hope? , 2000, Bulletin of the World Health Organization.

[30]  M. Molyneux,et al.  Severe and complicated malaria. Second edition. World Health Organization Division of Control of Tropical Diseases. , 1990 .

[31]  Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.